Case Study: How an Out-of-State Genomic Laboratory Achieved NYSDOH CLEP Approval for Its NGS Oncology Panel

Last updated: April 2026

Client details are presented in anonymized form consistent with IHS confidentiality obligations. Bracket placeholders indicate where client-specific data will be inserted prior to publication.

Client Overview

Organization type: [Molecular diagnostic laboratory / Commercial reference laboratory / Academic medical center laboratory / Clinical trial central laboratory]
Location: [State — outside New York]
Tests in scope: [e.g., NGS solid tumor oncology panel (X genes); pharmacogenomics panel; rare disease exome sequencing]
CLIA certificate: [High-complexity; CAP-accredited]
New York specimen volume: [X specimens/month from New York providers / New York-based clinical trial sites]
Reason for pursuing CLEP: [New York market access / Clinical trial enrollment at New York sites / Payer reimbursement acceleration / FDA safe harbor (pre-vacatur)]
Prior CLEP status: [No prior NYSDOH permit / Existing permit seeking to add new LDT categories]
Engagement start date: [Month, Year]
Permit issued: [Month, Year]
Outcome: NYSDOH CLEP permit issued; [X] LDTs approved

The Challenge

[Laboratory name] had been receiving referrals from [New York-based oncology practices / clinical trial sites] for [X months] when its compliance team discovered that testing New York specimens without a valid NYSDOH CLEP permit was unlawful under New York Public Health Law. The laboratory held CAP accreditation and a valid CLIA high-complexity certificate — neither of which satisfied NYSDOH's independent pre-market LDT review requirement.

The laboratory's legal and compliance leadership immediately halted New York specimen testing and engaged IHS to navigate the CLEP approval process as quickly as possible. The business impact of the testing halt — [X specimens/month, approximately $X in annual revenue from New York sources] — created significant urgency around the engagement timeline.

Four specific challenges defined the engagement:

1. Lab Director Certificate of Qualification (CQ) — The Unmovable Timeline Constraint

NYSDOH requires the Laboratory Director to hold a New York State Certificate of Qualification in the exact testing categories before the facility can submit its application. [Laboratory name]'s Laboratory Director, [Dr. Name], held board certifications in [specialty] and [specialty], but had not applied for New York CQ in the [Molecular Pathology / Molecular Diagnostics / Oncology] categories required for the NGS panel submission.

NYSDOH processes CQ applications independently — IHS cannot accelerate this step. It is a 2 to 4 month process that must be initiated immediately at engagement start. While the CQ application was pending, IHS used the lead time to build every other element of the submission package so that the facility application could be submitted the moment the CQ was issued.

2. Clinical Validity Documentation for High-Risk NGS Panel

[Laboratory name]'s NGS solid tumor panel was classified as High Risk under NYSDOH's tiered risk system — requiring full technical review before any conditional approval. The most demanding documentation requirement: clinical validity evidence (literature or trial data) demonstrating that each claimed variant detection capability performed as described in the intended use claim. The laboratory's existing validation documentation met CLIA performance standards but did not address clinical validity in the form NYSDOH requires.

3. Quality Management System Documentation Gaps

While [laboratory name] operated a functioning QMS under CAP accreditation requirements, the QMS documentation was not formatted to satisfy NYSDOH's Subpart 58-1 requirements. Annual internal audit records across all testing phases were not consistently documented. Formal CAPA records existed for PT failures but not for internal quality indicator misses. NYSDOH's QMS documentation standard is operationally more rigorous than CAP's — documented CAPA is mandatory for any quality event, not optional.

4. Out-of-State Compliance Complexity

[Laboratory name] had no prior experience with NYSDOH's regulatory framework. As an out-of-state laboratory, it faced additional obligations that in-state labs do not: GAR calculation based on New York-only specimen revenue (not global revenue); all NYSDOH surveyor travel expenses for the on-site inspection; and a regulatory relationship with a state agency that the laboratory had no prior interactions with and no internal staff familiar with its processes.

IHS's Approach

Day 1: Lab Director CQ Application Initiated

IHS's first action was to prepare Dr. [Name]'s CQ application for NYSDOH in the [Molecular Pathology / Molecular Diagnostics] categories required for the NGS panel submission. IHS assembled the required credentials documentation — board certifications, training records, laboratory experience documentation — and submitted the CQ application to NYSDOH on [date]. The CQ application was submitted [X days] after engagement start. From that point, the CQ processing timeline was NYSDOH-controlled.

Weeks 1–3: Gap Assessment

IHS reviewed [laboratory name]'s existing SOPs, validation data, QMS documentation, and personnel records against NYSDOH CLEP standards. Risk classification of the [X] proposed LDTs was assessed. The gap report identified [X] documentation categories requiring development or substantial revision before submission. The clinical validity documentation gap for the High-Risk NGS panel was identified as the highest-priority, highest-complexity item in the engagement.

Months 1–4: Documentation Build

Clinical Validity Package (High-Risk NGS Panel)

IHS assembled the clinical validity documentation package for the NGS oncology panel, drawing on [X] peer-reviewed publications and [X] internal validation studies. The package addressed clinical validity for each variant class detected by the panel: single nucleotide variants, insertions/deletions, copy number alterations, and gene fusions. IHS worked with [laboratory name]'s bioinformatics team to document the variant classification pipeline, reference database versions, and analytical sensitivity and specificity data across all variant classes — the documentation infrastructure NYSDOH requires for High-Risk molecular panels that no existing public guidance fully describes.

SOP Development

IHS drafted [X] SOPs covering all pre-analytic, analytic, and post-analytic processes for the NGS panel and [X] additional LDTs in scope. SOPs were developed at the operational specificity level NYSDOH requires: specimen identification, rejection criteria, reagent preparation procedures, QC frequency by assay phase, and result reporting with uncertainty documentation. IHS also drafted the [X] SOPs required for the supporting laboratory systems: environmental monitoring, equipment calibration, personnel training, and CAPA management.

QMS Documentation Update

IHS restructured [laboratory name]'s QMS documentation to meet NYSDOH Subpart 58-1 requirements. Annual internal audit documentation was rebuilt from the quality records available for [X] prior audit cycles. CAPA records were extended to cover internal quality indicator misses — not just PT failures — with a standardized CAPA form that captured root cause analysis, corrective action, effectiveness verification, and closure documentation.

Risk Attestation Form and Category-Specific Checklists

IHS completed the Risk Attestation Form for each LDT in scope, with supporting data citations for each response. The Genetic Testing-Molecular category checklist was completed for the NGS panel. The General checklist was completed for [X] additional LDTs. IHS's pre-submission review identified [X] responses in the Risk Attestation Form that could trigger RFIs — these were revised with additional supporting documentation before submission.

Month 4–5: Preliminary Submission

CQ for Dr. [Name] was issued by NYSDOH on [date] — [X weeks] after application, within the expected 2–4 month window. Facility application submitted via eCLEP portal immediately upon CQ issuance: facility demographics, ownership disclosures, Facility Personnel Form through HCS, proficiency testing provider authorization. NYSDOH assigned risk tiers within [X weeks]: [X LDTs assigned High Risk; X assigned Moderate Risk; X assigned Low Risk].

RFI Response (Month [X])

[Laboratory name] received [X RFIs / one RFI / no RFIs] from NYSDOH [X weeks] after preliminary submission. [If RFI received:] The RFI addressed [describe RFI content — e.g., "additional clinical validity citations for the copy number alteration detection claims in the NGS panel, and clarification of the QC acceptance criteria for the fusion detection assay"]. IHS drafted technically precise responses addressing each NYSDOH question in both digital and hard copy formats. The RFI response was submitted [X days] after receipt — well within the 60-day deadline that, if missed, would have caused automatic application inactivation.

On-Site Survey (Month [X])

NYSDOH CLEP surveyors conducted the on-site inspection at [laboratory name]'s [state] facility over [X days]. [Laboratory name] paid all NYSDOH surveyor travel expenses. IHS prepared all laboratory personnel for surveyor interactions: QMS documentation walk-through, competency demonstration protocols, equipment calibration log presentation, and result reporting procedure review. Surveyor assessment focused on [describe focus areas — e.g., "the bioinformatics pipeline documentation for the NGS panel, variant classification criteria, and the CAPA records for the two PT results flagged in the QMS review"].

Outcome

[Laboratory name] received its NYSDOH CLEP permit [X months] after engagement start. The permit covered [X LDTs], including the High-Risk NGS solid tumor oncology panel and [X] additional Moderate- and Low-Risk tests. Permit details:

[X] LDTs approved without conditions
[X] LDTs approved with minor documentation clarifications (resolved before permit issuance)
Annual permit cycle established (July 1 – June 30); first renewal due [date]

Operational Impact

New York market access restored: [Laboratory name] resumed accepting New York specimens [X days] after permit issuance. [X specimens/month] within [X weeks] of restoration, growing to [X specimens/month] within [X months]
Payer reimbursement: NYSDOH CLEP approval submitted to [X Medicare MACs / commercial insurers] as clinical validity evidence; reimbursement decisions received for [X payers] within [X months]
Clinical trial enrollment: [If applicable — New York site enrollment resumed for [trial name], adding [X] subjects to the trial within [X months] of permit issuance]
M&A / due diligence value: [If applicable — CLEP approval was noted in the [X] acquisition due diligence review as a positive compliance indicator, contributing to [describe valuation outcome]]
QMS improvement: The CAPA system rebuild — extending from PT failures to all quality indicator misses — materially improved [laboratory name]'s quality event response time from [X days] to [X days] average closure

Key Lessons for Laboratories Pursuing NYSDOH CLEP Approval

The Lab Director CQ Is the Critical Path Item — Start It First

Every other element of CLEP preparation can run in parallel. The Lab Director CQ cannot. NYSDOH processes CQ applications on its own timeline — 2 to 4 months is typical, and this step cannot be accelerated. Any laboratory beginning CLEP preparation must submit the CQ application on Day 1 of the engagement, not after the documentation build is complete.

Clinical Validity Documentation Is Not Method Validation

CLIA-standard method validation documentation — precision, accuracy, LoD, analytical specificity — is necessary but not sufficient for NYSDOH CLEP approval of High-Risk tests. NYSDOH requires clinical validity evidence: literature or trial data demonstrating that the test performs as claimed in its intended use context. For NGS oncology panels, this requires a structured literature review organized by variant class, supported by internal validation data. Laboratories that submit CLIA-standard validation packages without clinical validity supplements generate predictable RFIs.

54% of Applications Receive RFIs — Anticipate Them, Don't Fear Them

An RFI is not a rejection — it is a technical question. The 54% RFI rate means that receiving an RFI is the norm, not an indication of a deficient application. What matters is having the documentation infrastructure to respond substantively within the 60-day window. IHS pre-addresses common RFI triggers in the initial submission package to minimize rounds, and manages the response process as a primary project management function when RFIs are received.

Out-of-State Labs Face Additional Obligations That Need Explicit Planning

GAR calculation based on New York-only revenue requires accounting isolation of New York specimen revenue before the annual maintenance fee can be accurately projected. NYSDOH surveyor travel expense payment requires budget planning — the expense is real and can be significant depending on the laboratory's location relative to Albany. These obligations are not widely documented and catch many first-time CLEP applicants unprepared. IHS builds explicit out-of-state compliance planning into every non-New York laboratory engagement.

Is Your Laboratory Preparing for NYSDOH CLEP Approval?

Schedule a no-obligation gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your laboratory's current compliance posture against NYSDOH CLEP requirements and give you a clear roadmap to permit issuance — including Lab Director CQ planning, clinical validity documentation strategy, and RFI risk mitigation.

Schedule Your CLEP Gap Assessment